The latest NICE response confirms that NWBO hasn’t even submitted evidence for reimbursement assessment, let alone entered any pilot program for early access or collaboration. That’s not just a delay it’s a signal. Combine that with the fact that NWBO hasn’t staffed up in the UK for commercial sales, not through themselves and not via Advent. No commercial team. No distribution hires. No sales infrastructure. Nothing.
This is telling. NWBO has repeatedly stated that they plan to “franchise” DCVax-L. In other words, they don’t plan to sell it themselves — they intend to hand it off, either through licensing or outright sale, to a pharmaceutical partner who will handle market entry.
So what’s the logical conclusion? MHRA approval isn’t the start of commercialization for NWBO. It’s their exit strategy. Approval is the asset they’re working to hand over. They’re not preparing to commercialize; they’re preparing to transfer.
Unless you believe NWBO is simply incompetent to the core — and forgot that approval without NICE submission or a sales team means no revenue, this is the most rational explanation.
They’re not building to launch DCVax. They’re building to sell it.
And that is what I keep telling you all
If Linda Powers genuinely intends to commercialize DCVax-L herself, then she’s putting Advent at risk by not preparing for post-approval market access. Advent is NWBO’s manufacturing arm. It’s staffed with skilled professionals. By failing to engage NICE and move toward actual sales, NWBO is leaving Advent’s commercial future in limbo.
You can only run manufacturing dry-runs and prototype batches for so long. Staff won’t stay if they see no product shipping, no scaling, no market traction. Eventually, Advent itself becomes financially unsustainable. Powers might hate external critics or shareholders. But she supposedly values Advent — it’s been her core manufacturing asset for years. If she believed in commercialization, she’d be preparing to feed volume to Advent post-approval.
So what’s more likely? NWBO is not preparing for commercial rollout because they never intended to run sales themselves. They’re holding Advent as part of the package to license or sell, not as a standalone revenue engine. Something I have also been saying for years, both Advent and NWBO will be sold in a package deal, not just NWBO.
If Powers plans to sell DCVax-L, then Advent is just a factory for the buyer.
If not? Then yes — she’s steering both NWBO and Advent straight into the ground.
You see a glass half full completly empty. I see a company that is in the works to get sold.
Market Data 
Markets 
AI
